Viracta Therapeutics, Inc. Share Price Nasdaq
Equities
US92765F1084
Biotechnology & Medical Research
Sales 2024 * | - | Sales 2025 * | 2.33M 184M | Capitalization | 32.99M 2.6B |
---|---|---|---|---|---|
Net income 2024 * | -62M -4.89B | Net income 2025 * | -83M -6.55B | EV / Sales 2024 * | - |
Net cash position 2024 * | - 0 | Net cash position 2025 * | - 0 | EV / Sales 2025 * | 14.1 x |
P/E ratio 2024 * |
-0.73
x | P/E ratio 2025 * |
-0.78
x | Employees | 40 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 97.2% |
Latest transcript on Viracta Therapeutics, Inc.
Managers | Title | Age | Since |
---|---|---|---|
Mark Rothera
CEO | Chief Executive Officer | 61 | 18/09/22 |
Chief Tech/Sci/R&D Officer | - | - | |
Darrel Cohen
CTO | Chief Tech/Sci/R&D Officer | 59 | 06/08/23 |
Members of the board | Title | Age | Since |
---|---|---|---|
Ivor Royston
BRD | Director/Board Member | 79 | 30/09/07 |
Thomas Darcy
BRD | Director/Board Member | 74 | 31/01/21 |
Barry Simon
BRD | Director/Board Member | 59 | 02/03/21 |
1st Jan change | Capi. | |
---|---|---|
+33.35% | 49.46B | |
+1.64% | 42.58B | |
+49.11% | 42.49B | |
-4.22% | 29.09B | |
+11.53% | 26.61B | |
-22.73% | 18.64B | |
+8.20% | 13.16B | |
+29.14% | 12.55B | |
+24.33% | 12.1B |